Altered serotonergic neurotransmission may contribute to the non-motor features commonly associated with Parkinson's disease (PD) such as sleep disorders. The 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin and melatonin. The purpose of this study was to compare the effects of 5-HTP to placebo on REM sleep behavior disorder (RBD) status in patients with PD.

Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease

Meloni, Mario;Figorilli, Michela;Carta, Manolo;Tamburrino, Ludovica;Sanna, Fabrizio;Defazio, Giovanni;Puligheddu, Monica
2022-01-01

Abstract

Altered serotonergic neurotransmission may contribute to the non-motor features commonly associated with Parkinson's disease (PD) such as sleep disorders. The 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin and melatonin. The purpose of this study was to compare the effects of 5-HTP to placebo on REM sleep behavior disorder (RBD) status in patients with PD.
2022
5-Hydroxytryptophan; Melatonin; Parkinson’s disease; REM sleep behavior disorder; Serotonin
File in questo prodotto:
File Dimensione Formato  
Meloni2021_Article_PreliminaryFindingOfARandomize.pdf

accesso aperto

Tipologia: versione editoriale (VoR)
Dimensione 818.04 kB
Formato Adobe PDF
818.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/317155
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact